Alzheimer's disease

People with multiple sclerosis (MS) are at a greater risk than the general public of developing any type of dementia, with that of Alzheimer’s disease being more than twice as high and vascular dementia nearly four times as high, a study from Korea suggested. This risk also was higher…

NervGen Pharma has received approval to enroll a third and final group of healthy volunteers in the multiple ascending dose (MAD) segment of its Phase 1 clinical trial of NVG-291, an investigational treatment for multiple sclerosis (MS) and other nervous system diseases. A safety review committee cleared the…

  Synaptogenix announced plans to advance bryostatin-1, its lead candidate, into clinical trials for multiple sclerosis (MS), marking the third neurological disease the small molecule therapy is being developed to potentially treat. “Multiple sclerosis joins Alzheimer’s disease (“AD”) and Fragile X syndrome as our third indication with potential clinical…

Treatment of up to a year with memantine — an approved therapy for Alzheimer’s disease — failed to prevent cognitive decline and disability, and to significantly reduce fatigue and spasticity in adults with multiple sclerosis (MS), a review of published studies shows. The therapy, sold under the brand name Namenda, works…

NeuroScientific Biopharmaceuticals (NSB)’s lead candidate EmtinB induces significantly greater myelin regeneration in a cellular model of multiple sclerosis (MS) than the market-leading therapy Copaxone, the company announced. “These results represent a potential breakthrough in the treatment of MS as there are currently no approved therapeutic drugs available to patients that…

People with multiple sclerosis (MS) and other neurological diseases have a significantly higher aluminum content in their brains than those with no known neurological impairment and no identifiable neurodegenerative disease, a recent study found. The research further supports a role of aluminum in the development of these brain conditions,…

People living close to major roads or highways are at a greater risk of multiple sclerosis (MS), a database study of people in metropolitan Vancouver reports. Parks and other green spaces in urban areas that might lower exposure to air pollutants did not affect a person’s overall risk of developing MS,…

Scientists have found that a usually-overlooked signal from MRI scans indicates brain regions of nerve cell death and may help in the understanding of brain development and the early diagnosis of brain disorders like multiple sclerosis (MS),…

Scientists at Russia’s Tomsk Polytechnic University (TPU) and Siberian State Medical University (SSMU), both in Tomsk, have developed a diagnosis system for neurodegenerative diseases in the early stages. The system uses virtual reality (VR) technology to immerse a subject in a virtual environment during functional tests designed to detect early symptoms of…

Mitochon Pharmaceuticals announced the completion of a second year of financing, raising a total $1.6 million to advance its lead compound, MP101, a mitochondrial targeted neuro-protective agent, into clinical testing. The company is developing mitochondrial modulators for patients with neurodegenerative diseases ranging from Alzheimer’s and Parkinson’s to multiple sclerosis (MS). A number of studies have…

AB Science recently reported the publication of four peer-reviewed and independent research papers that add to the growing recognition of masitinib, the company’s lead compound, as a promising treatment for neurological and neurodegenerative diseases, including progressive multiple sclerosis (MS), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS). Tyrosine kinase inhibitors (TKIs)…

Researchers have isolated the particular cell types likely to initiate common brain disorders and diseases, such as multiple sclerosis (MS) and Alzheimer’s disease, a finding that may point the way to new and targeted treatments. The brain has a complex cellular architecture characterized by a diverse set of cell types that are…